Skip to main content
Clinical Trials/NCT02292043
NCT02292043
Unknown
Not Applicable

Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction

Harbin Medical University2 sites in 1 country60 target enrollmentStarted: May 2013Last updated:
InterventionsHTEA
DrugsHTEA

Overview

Phase
Not Applicable
Sponsor
Harbin Medical University
Enrollment
60
Locations
2
Primary Endpoint
Morbidity

Overview

Brief Summary

The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction.

Detailed Description

The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction. The specific index is 6 miniutes walk distance, echocardiography, NYHA, NTproBNP level, peripherial WBC, RBC, PLT, Cre, UA, K+, Na+ upon entrance to hospital and 4 weeks after HTEA treatment, and 3 months after discharge. The morbidity and re-hospitalization would also calculated 3 months after discharge.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
20 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 90 chronic cardiac failure patients in our hospital were selected and divided into two groups.

Exclusion Criteria

  • Vavular diseases

Arms & Interventions

idiopathic dilated cardiomyopathy group

idiopathic dilated cardiomyopathy group treated with HTEA

Intervention: HTEA (Drug)

post-myocardial infarction group

post-myocardial infarction group treated with TEA

Intervention: HTEA (Drug)

Outcomes

Primary Outcomes

Morbidity

Time Frame: 1 months to 3 months after discharge

Secondary Outcomes

  • The decreased degree of NT-proBNP higher than 30%(3 months after discharge)

Investigators

Sponsor
Harbin Medical University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Wei Liu

Prof. Liu

Harbin Medical University

Study Sites (2)

Loading locations...

Similar Trials